MARKET

ARTV

ARTV

ARTIVA BIOTHERAPEUTICS INC
NASDAQ
4.650
+0.330
+7.64%
After Hours: 4.640 -0.01 -0.22% 19:47 12/18 EST
OPEN
4.420
PREV CLOSE
4.320
HIGH
4.750
LOW
4.370
VOLUME
493.81K
TURNOVER
--
52 WEEK HIGH
11.55
52 WEEK LOW
1.470
MARKET CAP
114.13M
P/E (TTM)
-1.4327
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 2d ago
Artiva Biotherapeutics CEO Fred Aslan Reports Sale of Common Shares
Reuters · 3d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 3d ago
Crude Oil Falls Over 1%; US Homebuilder Sentiment Edges Higher In December
Benzinga · 3d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 3d ago
US Stocks Mixed; NY Manufacturing Activity Dips In December
Benzinga · 3d ago
Weekly Report: what happened at ARTV last week (1208-1212)?
Weekly Report · 3d ago
Wedbush Predicts Up to 600% Jump for These 2 ‘Strong Buy’ Stocks
TipRanks · 5d ago
More
About ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Webull offers Artiva Biotherapeutics Inc stock information, including NASDAQ: ARTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTV stock methods without spending real money on the virtual paper trading platform.